Latest in News & Research

Response-Adapted Treatment De-escalation Cost-Effective in Melanoma

Response-adapted de-escalation of immunotherapy yielded incremental net monetary benefit of $28,849 versus standard of care
By Dermsquared Editorial Team | | October 19, 2022

Side Effect and Life-Long Use Concerns Are Barriers to Minoxidil Use

Main reason for stopping minoxidil is lack of effectiveness
By Dermsquared Editorial Team | | October 19, 2022

Comorbidity Burden Higher in Generalized Pustular Psoriasis

Most prevalent conditions in GPP were hypertension, psoriatic arthritis, type 2 diabetes, hyperlipidemia
By Physician’s Briefing Staff | | October 19, 2022

Online Symptom Checkers Often Not Accurate for ID'ing Skin Rashes

Even when correct in diagnosis, broad differentials and low specificity of results contribute to diagnostic uncertainty
By Physician’s Briefing Staff | | October 18, 2022

COVID-19 Mainly Mild, Moderate in Eczema Patients Receiving Tralokinumab

76 of 77 patients with COVID-19 were unvaccinated; no new safety signals reported after COVID-19 vaccination
By Dermsquared Editorial Team | | October 12, 2022

Instruments ID'd for Measuring Eczema Control, Itch Intensity

Consensus reached for Recap of Atopic Eczema and Atopic Dermatitis Control Tool for measuring eczema control
By Dermsquared Editorial Team | | October 12, 2022

Lenabasum Studied for Refractory Cutaneous Dermatomyositis

Results of phase 2 study suggest clinical benefit and favorable safety profile, warranting further study of lenabasum for DM
By Physician's Briefing Staff | | October 11, 2022

Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma

Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition
By Physician’s Briefing Staff | | October 06, 2022

High Sunburn Frequency Through Life Linked to Melanoma, cSCC Risk

Stable high and high-to-low trajectories had increased risks compared with stable low trajectory
By Dermsquared Editorial Team | | October 05, 2022

More Eczema Patients Achieve Itch-Free State With Ruxolitinib

Difference in itch numerical rating scale 0/1 was significant on day 2 and persisted through week 8
By Dermsquared Editorial Team | | October 05, 2022

IV Immune Globulin Bests Placebo for Dermatomyositis

More adults receiving IVIG versus placebo had Total Improvement Score of at least 20 at 16 weeks
By Physician's Briefing Staff | | October 05, 2022

Apremilast May Offer Cardiometabolic Benefit in Psoriasis Patients

5 to 6 percent decrease seen in subcutaneous and visceral adiposity at week 16 of treatment, which was maintained at 52 weeks
By Physician’s Briefing Staff | | October 04, 2022

FDA Approves Dupixent for Prurigo Nodularis

This priority review-based approval makes Dupixent the first treatment for the inflammatory skin condition
By Physician’s Briefing Staff | | September 30, 2022

Is Long-Term Tapinarof Cream Safe, Effective for Psoriasis?

For up to one year, 40.9 percent of patients achieved complete disease clearance with a four-month remittive effect; no new safety signals seen
By Dermsquared Editorial Team | | September 28, 2022

Sentinel Lymph Node Biopsy Status Predicts Melanoma Survival

SLN positivity significantly associated with lower five-year disease-specific survival among patients with clinical stage IIB/C cutaneous melanoma
By Dermsquared Editorial Team | | September 28, 2022

Inflammatory Bowel Disease, Psoriasis May Be Causally Related

Genetic predisposition to psoriasis not linked to total IBD, but is associated with Crohn disease
By Physician's Briefing Staff | | September 22, 2022

Several Factors Significantly Tied to Atopic Dermatitis Disease Burden

Strongest associations seen for disease severity and time spent managing symptoms
By Physician’s Briefing Staff | | September 22, 2022

Roflumilast Yields Better Results for Chronic Plaque Psoriasis

Two multicenter trials show significantly greater percentage of patients treated with roflumilast versus vehicle had IGA success at week 8
By Dermsquared Editorial Team | | September 21, 2022

Burden of Ambulatory Hidradenitis Suppurativa Visits Up During Summer

51 percent of ambulatory visits for hidradenitis suppurativa occurred during May to August
By Dermsquared Editorial Team | | September 21, 2022

Psoriasis Patients Find Psoriatic Arthritis Screening Worthwhile

Participants report feeling empowered by comprehensive screening
By Physician’s Briefing Staff | | September 20, 2022

Dupilumab Eases Atopic Dermatitis in Children Younger Than 6 Years

Signs and symptoms of atopic dermatitis improved with dupilumab versus placebo in addition to topical corticosteroids
By Physician’s Briefing Staff | | September 19, 2022

Is Efficacy of Itraconazole for Tinea Corporis/Cruris Higher With Greater Dose?

400-mg dose of itraconazole achieves higher cure rate, but cost is 120 percent greater compared with 100-mg dose
By Dermsquared Editorial Team | | September 14, 2022

Few Europeans Use Photoprotection All Year Round

Only 56 percent of Europeans were aware that sun protection is useful when weather is overcast
By Dermsquared Editorial Team | | September 14, 2022

24 of 1200

Headline from the Week of February 09 - 15, 2026

Second Annual National Cancer Database Report Presented for 2022

By Elana Gotkine (HealthDay News) | | February 11, 2026

Presurgical Pembrolizumab Beneficial for Desmoplastic Melanoma

By Elana Gotkine (HealthDay News) | | February 11, 2026